Navigation Links
Researchers Train the Immune System to Deliver Virus That Destroys Cancer in Lab Models
Date:12/18/2007

Procedure also could prevent recurrence

ROCHESTER, Minn., Dec. 18 /PRNewswire-USNewswire/ -- An international team of researchers led by Mayo Clinic have designed a technique that uses the body's own cells and a virus to destroy cancer cells that spread from primary tumors to other parts of the body through the lymphatic system. In addition, their study shows that this technology could be the basis for a new cancer vaccine to prevent cancer recurrence.

The study appeared in the Dec. 9 online issue of Nature Medicine.

The technology combines infection-fighting T-cells with the vesicular stomatitis virus that targets and destroys cancer cells while leaving normal cells unharmed. The study, which has not yet been replicated in humans, is significant because it describes a potential new therapy to treat and prevent the spread of cancer in patients.

"We hope to translate these results into clinical trials. However, until those trials are done, it's difficult to be certain that what we see in mouse models will clearly translate to humans. We're hopeful that will be the case," says Richard Vile, Ph.D., a Mayo Clinic specialist in molecular medicine and immunology and the study's principal investigator.

In primary cancers of the breast, colon, prostate, head and neck and skin, the growth of secondary tumors often pose the most threat to patients, not the primary tumor. The prognosis for these patients often depends upon the degree of lymph node involvement and whether the cancer has spread.

Dr. Vile and colleagues theorized that they could control the spread of cancer through the lymphatic system (bone marrow, spleen, thymus and lymph nodes) by manipulating the immune system.

Researchers zeroed in on immature T-cells from bone marrow, programming them to respond to specific threats to the immune system while delivering a cancer-destroying virus to the tumor cells.

To deliver the virus, researcher
'/>"/>

SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
6. U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos
11. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... INDIANAPOLIS , May 28, 2015  Eli Lilly and ... of its previously announced cash tender offer for up to ... debt securities. Holders of notes who tendered, and ... p.m., New York City time, on ... accepted for purchase by Lilly, are eligible to receive the ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... Dec. 16, 2010 Solta Medical, Inc. (Nasdaq: ... tightening and a market leader in aesthetic skin treatments, today ... revolutionary Thermage and Fraxel devices that have helped to build ... device industry. The milestone reflects how much the ...
... 2010 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... today announced that it has provided notice of voluntary ... Business Financial Services Inc. and Silicon Valley Bank.  The ... on the facility, including interest and other fees payable ...
Cached Medicine Technology:Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 2Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 4
(Date:5/30/2015)... May 30, 2015 Twelve of the ... by their peers as the 2015 Giants of ... at the Chicago Illuminating Company last night. The awardees ... oncologists for landmark achievements in translational research, gene therapy, ... course of cancer treatment. , Honorees were introduced and ...
(Date:5/30/2015)... You've probably heard that using cotton swabs to clean the ... found a better way to remove ear wax? Luckily, a ... need. , They developed SUNDENG EAR CLEANER to ease the ... from the ears. What's more, it is safer and more ... today for children and adults of all ages. As such, ...
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2
... unlikely to be caused by a decrease in mammography screening, ... Journal of the National Cancer Institute . It is ... , There has been a recent, rapid decline in ... Initiative study found that hormone therapy was associated with an ...
... B: apo A-I ratio is not a better predictor ... that include total cholesterol and HDL-C, according to a ... Current risk-prediction instruments and guidelines for coronary heart disease ... (LDL-C), total cholesterol, or both for CHD risk assessment. ...
... can diagnose venous thromboembolic disease (VTED) in cancer patients ... the thorax, abdomen, and pelvis which are regularly done ... according to a recent study conducted by radiologists at ... , Venous thromboembolic disease can be fatal if left ...
... warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are ... diseases. In this study, Joseph Delaney MSc, Dr. ... in 4,028 cases with a diagnosis of gastrointestinal ... Kingdom. They documented a 46-fold increase in the ...
... Spirometry testing is a widely accepted and encouraged ... new research shows that it is not used nearly ... CHEST, the peer-reviewed journal of the American College of ... patients with a COPD diagnosis ever received spirometry testing. ...
... in a nursing home or take medication to lower ... following hospitalization for heatstroke, according to a study posted ... issue of Archives of Internal Medicine, one of the ... online today found that being confined to bed, not ...
Cached Medicine News:Health News:Drop in breast cancer incidence linked to hormone use, not mammograms 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Study says COPD testing is not measuring up 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: